Katarzyna Kuncewicz

This study identifies cyclic peptide ligands targeting CAPON, showing reduced neuronal toxicity and tau phosphorylation under Alzheimer's disease stress conditions.

This study identifies cyclic peptides that bind TREM2 and modulate microglial responses under amyloid stress, suggesting their potential as neuroimmune therapeutics.

This paper designs AI-generated cyclic peptides that modulate the CD28 immune checkpoint with controllable pharmacology and therapeutic efficacy in preclinical models.

This study introduces CP8, a cyclic peptide that effectively blocks CD28 co-stimulation and allows rapid restoration of T-cell function, outperforming existing biologics under exposure-limited conditions.

This paper identifies a small molecule TREM2 modulator, EN020, that enhances microglial phagocytosis better than a known agonist.

The paper designs cyclic peptides targeting TREM2 using AI tools and validates their binding and stability.

As48 is a small molecule that activates TREM2 and inhibits its shedding, offering a dual mechanism to enhance microglial function in Alzheimer's disease.

This paper identifies first-in-class small molecule agonists of TREM2 through DEL screening, validates their binding and function, and suggests a novel activation mechanism.

This paper develops a high-throughput screening platform to identify small molecule TREM2 binders using TRIC technology, finding four validated hits with moderate binding affinities.

This paper describes the discovery of C1, an achiral TREM2 agonist with improved pharmacokinetics and validated target engagement compared to VG-3927.

This paper discovers and validates a first-in-class small molecule inhibitor of the SLIT2/ROBO1 interaction using DNA-encoded library screening and demonstrates its functional inhibition and ADME properties.